Curis announces removal of FDA partial clinical hold on CUDC-427 Curis reported that the FDA has notified the company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND. The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.
News For CRIS From The Last 14 Days
Check below for free stories on CRIS the last two weeks.